WYETH-AYERST COMMITS TO CHARACTERIZATION OF PREMARIN, FDA SAYS; GENERIC CONJUGATED ESTROGENS MAY NOT BE APPROVED UNTIL PREMARIN IS CHARACTERIZED
Executive Summary
Wyeth-Ayerst has committed to characterizing the composition of Premarin, FDA said in a May 5 memorandum explaining its current decision not to approve generic versions of the conjugated estrogens product.
You may also be interested in...
Premarin Generics Reined In; Barr Supplier “Cannot Be Trusted,” Judge Says
Natural Biologics lacks the expertise to reproduce Wyeth's estrogen extraction process for conjugated estrogens (Premarin) by legitimate means, St. Paul, Minn. federal court Judge Joan Ericksen maintained in issuing a permanent injunction against the company
Premarin Generics Reined In; Barr Supplier “Cannot Be Trusted,” Judge Says
Natural Biologics lacks the expertise to reproduce Wyeth's estrogen extraction process for conjugated estrogens (Premarin) by legitimate means, St. Paul, Minn. federal court Judge Joan Ericksen maintained in issuing a permanent injunction against the company
Cenestin Settlement: Barr Boosts Branded Business With Five Wyeth Products
Barr will add an oral contraceptive in development at Wyeth as part of an acquisition deal that settles Cenestin antitrust litigation